A detailed history of Northern Trust Corp transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 358,573 shares of GLUE stock, worth $3.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
358,573
Previous 294,196 21.88%
Holding current value
$3.04 Million
Previous $1.1 Million 72.73%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.59 - $6.97 $231,113 - $448,707
64,377 Added 21.88%
358,573 $1.9 Million
Q2 2024

Aug 14, 2024

BUY
$3.38 - $7.86 $12,647 - $29,412
3,742 Added 1.29%
294,196 $1.1 Million
Q1 2024

May 14, 2024

BUY
$4.26 - $8.46 $23,515 - $46,699
5,520 Added 1.94%
290,454 $2.05 Million
Q4 2023

Feb 13, 2024

SELL
$2.5 - $5.93 $397,570 - $943,036
-159,028 Reduced 35.82%
284,934 $1.61 Million
Q3 2023

Nov 13, 2023

BUY
$4.78 - $7.22 $73,960 - $111,715
15,473 Added 3.61%
443,962 $2.13 Million
Q2 2023

Aug 11, 2023

BUY
$4.53 - $8.4 $806,167 - $1.49 Million
177,962 Added 71.04%
428,489 $2.94 Million
Q1 2023

May 15, 2023

SELL
$5.95 - $8.21 $27,274 - $37,634
-4,584 Reduced 1.8%
250,527 $1.95 Million
Q4 2022

Feb 13, 2023

BUY
$6.71 - $9.72 $46,708 - $67,660
6,961 Added 2.81%
255,111 $1.94 Million
Q3 2022

Nov 14, 2022

BUY
$7.17 - $12.16 $174,840 - $296,521
24,385 Added 10.9%
248,150 $2.03 Million
Q2 2022

Aug 12, 2022

BUY
$6.15 - $14.99 $24,766 - $60,364
4,027 Added 1.83%
223,765 $2.16 Million
Q1 2022

May 13, 2022

BUY
$10.36 - $20.41 $1.16 Million - $2.28 Million
111,573 Added 103.15%
219,738 $3.08 Million
Q4 2021

Feb 08, 2022

BUY
$16.28 - $27.15 $67,855 - $113,161
4,168 Added 4.01%
108,165 $2.21 Million
Q3 2021

Nov 15, 2021

BUY
$18.59 - $42.21 $1.93 Million - $4.39 Million
103,997 New
103,997 $2.32 Million

Others Institutions Holding GLUE

About Monte Rosa Therapeutics, Inc.


  • Ticker GLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,713,900
  • Market Cap $397M
  • Description
  • Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...
More about GLUE
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.